Who we are – a brief abstract of our background and activities  New developments are our strengths…
Hence it follows that we are taking a particular interest in new product developments and advanced manufacturing techniques for antiviral, cancerostatic and cardiovascular drug substances and for their key intermediates as well. It is in the nature of our activities that we put our main emphasis on Nucleotides, Nucleosides and their analogues. For Pharma Waldhof innovation, however, also means to steadily improve the traditionally high and recognized quality standard of its products and services. It is our aim not only to meet the growing requirements of the market and the regulatory conditions but rather to establish new standards at high level. Our environment – our skills, our ambitions…
The current range of biochemicals Pharma Waldhof roughly comprises 200 compounds enjoying regular scientific and commercial interest. Our new affiliation (since 2004) to the multinational ACETO group of companies, headquartered in the U.S., and our continued manufacturing and technical collaboration with Roche Diagnostics, Germany, our former parent company, and further cooperations with selected biotechnology companies and research institutions as well qualify us to flexibly respond to specific demands and developments in biochemistry and biotechnology, in pharmacy and diagnostics, in cosmetology and in nutrition physiology of today and tomorrow. |
 |
||
|
|
 |
|